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Unequivocal delineation of clinicogenetic subgroups and
development of a new model for improved outcome prediction in
neuroblastoma
Abstract
PURPOSE: Neuroblastoma is a genetically heterogeneous pediatric tumor with a remarkably variable
clinical behavior ranging from widely disseminated disease to spontaneous regression. In this study, we
aimed for comprehensive genetic subgroup discovery and assessment of independent prognostic
markers based on genome-wide aberrations detected by comparative genomic hybridization (CGH).
MATERIALS AND METHODS: Published CGH data from 231 primary untreated neuroblastomas
were converted to a digitized format suitable for global data mining, subgroup discovery, and
multivariate survival analyses. RESULTS: In contrast to previous reports, which included only a few
genetic parameters, we present here for the first time a strategy that allows unbiased evaluation of all
genetic imbalances detected by CGH. The presented approach firmly established the existence of three
different clinicogenetic subgroups and indicated that chromosome 17 status and tumor stage were the
only independent significant predictors for patient outcome. Important new findings were: (1) a normal
chromosome 17 status as a delineator of a subgroup of presumed favorable-stage tumors with highly
increased risk; (2) the recognition of a survivor signature conferring 100% 5-year survival for stage 1, 2,
and 4S tumors presenting with whole chromosome 17 gain; and (3) the identification of 3p deletion as a
hallmark of older age at diagnosis. CONCLUSION: We propose a new regression model for improved
patient outcome prediction, incorporating tumor stage, chromosome 17, and amplification/deletion
status. These findings may prove highly valuable with respect to more reliable risk assessment,
evaluation of clinical results, and optimization of current treatment protocols.
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A B S T R A C T
Purpose
Neuroblastoma is a genetically heterogeneous pediatric tumor with a remarkably variable
clinical behavior ranging from widely disseminated disease to spontaneous regression. In
this study, we aimed for comprehensive genetic subgroup discovery and assessment of
independent prognostic markers based on genome-wide aberrations detected by compara-
tive genomic hybridization (CGH).
Materials and Methods
Published CGH data from 231 primary untreated neuroblastomas were converted to a digitized
format suitable for global data mining, subgroup discovery, and multivariate survival analyses.
Results
In contrast to previous reports, which included only a few genetic parameters, we present here
for the first time a strategy that allows unbiased evaluation of all genetic imbalances detected by
CGH. The presented approach firmly established the existence of three different clinicogenetic
subgroups and indicated that chromosome 17 status and tumor stage were the only indepen-
dent significant predictors for patient outcome. Important new findings were: (1) a normal
chromosome 17 status as a delineator of a subgroup of presumed favorable-stage tumors with
highly increased risk; (2) the recognition of a survivor signature conferring 100% 5-year survival
for stage 1, 2, and 4S tumors presenting with whole chromosome 17 gain; and (3) the
identification of 3p deletion as a hallmark of older age at diagnosis.
Conclusion
We propose a new regression model for improved patient outcome prediction, incorporating
tumor stage, chromosome 17, and amplification/deletion status. These findings may prove
highly valuable with respect to more reliable risk assessment, evaluation of clinical results,
and optimization of current treatment protocols.
J Clin Oncol 23:2280-2299. © 2005 by American Society of Clinical Oncology
INTRODUCTION
Neuroblastoma is the most frequent ex-
tracranial solid tumor in children and
originates from neural crest– derived sym-
pathetic nerve cells. In contrast to many
other pediatric malignancies, progress in
treatment (especially for advanced-stage tu-
mors) has been relatively modest. Hence, at
present, this tumor still poses a major chal-
lenge to the clinical oncologist. Although
tumor stage and age at diagnosis are impor-
tant predictors for patient outcome and are
critical parameters for therapy stratification,
a significant number of patients with appar-
ently low-risk neuroblastoma at diagnosis
relapse and require more aggressive treat-
ment. Similarly, more than half of the
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patients with adverse prognostic features at present cannot be
cured, despite intensive multimodal therapy. In view of the
unpredictable tumor behavior, many studies have aimed at the
identification of additional factors for prognostic stratification.
Deletion of the short arm of chromosome 1, amplifica-
tion of the MYCN proto-oncogene, and diploidy or tet-
raploidy were recognized quite early as genetic markers for
aggressive neuroblastomas.1-3 However, the overall picture
of the different genomic changes in the various tumor stages
remained incomplete for a long time. The importance of
loss of chromosome regions other than 1p (ie, 2q, 3p, 4p,
9p, 11q, 14q, and 18q) was demonstrated by loss-of-
heterozygosity studies.4-6 Losses of 3p, 9p, and 11q may also
have prognostic value.7-10 A major landmark was the recog-
nition of the high incidence of unbalanced 17q rearrange-
ments by molecular cytogenetics, and the subsequent
demonstration that the resulting partial 17q gain was the
most powerful genetic predictor for poor outcome.11,12
Many of the aforementioned studies focused on one or
a few particular chromosomal regions. Hence, a compre-
hensive overview of the occurrence of the previously men-
tioned imbalances and their interrelationship could not be
obtained. As successful karyotyping was not possible for a
high proportion of neuroblastomas, it was not until the
introduction of comparative genomic hybridization (CGH)
that screening for DNA copy number gains and losses across
the entire genome became feasible.13,14 This approach indeed
proved to be particularly useful to address this issue, and con-
sequently led to more general insights into the genetic hetero-
geneity of this enigmatic childhood tumor.15-21 Among others,
evidence was obtained for a new genetic subgroup of MYCN
single-copy neuroblastomas, characterized by loss of 11q, of-
ten in association with loss of 3p.15,20,21
Despite these significant new findings, published CGH
data formats for representation of gains and losses (either
ideogram or International System for Human Cytogenetic
Nomenclature [ISCN] description) do not allow in-depth
analysis of large series of tumors. Here we illustrate the use
of an available online tool for conversion of conventional
CGH data into a digitized format (a band-specific aberra-
tion matrix) amenable for a more comprehensive genetic
subgroup discovery. Global data mining and multivariate
survival analyses on 231 published CGH results from neu-
roblastoma tumors firmly established the existence of three
major clinicogenetic subgroups in neuroblastoma and pro-
vided to be a comprehensive assessment of prognostic pa-
rameters with independent power, leading to identification
of a survivor signature for neuroblastoma and a new math-
ematical model for improved outcome prediction.
MATERIALS AND METHODS
Tumor Samples
Previously published CGH data on primary neuroblastoma
tumors were included in this study based on the availability of
both individual band-specific CGH results for each tumor, as well
as clinical patient information (stage, age at diagnosis, progres-
sion, and survival status). Samples without genetic aberration
were excluded. This yielded a compilation of 231 unique cases
from eight publications,15-22 of which 195 were also part of an-
other multicenter study on 313 cases.11 In this previous study, the
consistency of the CGH data among five European centers (from
which the majority of the cases in this study originate) was as-
sessed, and no significant differences between laboratories were
detected. Each referenced study has properly validated their CGH
methodology and results. Where possible, clinical information
was updated with respect to the original publication. All CGH
aberration data can be accessed through the public Progenetix
repository,23 under ICD-O-3 (International Classification of Dis-
eases for Oncology) code 9500/3. The sample identifiers from the
Progenetix neuroblastoma case table are identical to those in the
Supplemental Table (available online only in the full-text version;
it is not included in the PDF [via Adobe® Acrobat Reader®]
version), and are linked to the original publication (PubMed
number) and CGH aberration pattern. Tumor stage was defined
according to the International Neuroblastoma Staging System,24
and risk status, according to the International Neuroblastoma
Pathology Classification.25 Event-free survival was defined as the
time between initial diagnosis and relapse or death, or time be-
tween diagnosis and last follow-up if no event had occurred. The
patients were treated according to the national protocols adapted
to age and stage in use at that time in their country. Stratified
survival analyses indicated that there were no significant differ-
ences in patient outcome in the various countries, considering
either all patients together, or only the stage 4 tumors, or only
infants (for these three groups, sufficient samples were available
for reliable analysis; data not shown). The introduction of more
homogeneous treatment regimens through the recently created
International Society of Pediatric Oncology (SIOP) –Europe Neu-
roblastoma Group will allow confirmation of our results in a
prospective study.
CGH Data Conversion
The ISCN2matrix converter at Progenetix23 was used for
both online conversion of the chromosome aberration list in ISCN
format to a band-specific aberration matrix, as well as generation
of a band-specific graphical representation of chromosomal gains
and losses. During the conversion process, the CGH-based ISCN
reverse in situ hybridization annotated karyotype (Supplemental
Table) is resolved into 393 chromosome bands with categorical
variables indicating the aberration status (1: loss; 0: normal;1:
gain;2: amplification), resulting in an average size of 7.9 mega-
bases per annotation unit (band), well in the range of the spatial
resolution achieved by chromosomal CGH.26
Exploratory Data Mining and Statistical Analysis
The J-Express version 2.1 package27 was used for exploratory
data mining, such as principal component analysis (PCA) and
hierarchical clustering. PCA is a mathematical procedure to re-
duce the dimensionality of the data by transforming a high num-
ber of (possibly) correlated variables (ie, chromosome bands) into
a (smaller) number of uncorrelated (independent) variables called
principal components. The first principal component accounts for
as much of the variability in the data as possible, and each succeed-
ing component accounts for as much of the remaining variability
as possible. Mapping of the original variables onto the first two or
three principal components (in a 2-D or 3-D plot, respectively)
Mining of Neuroblastoma CGH Data
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provides a way to detect structure in the data and to classify
variables. Cluster analysis is a technique used for combining vari-
ables (ie, chromosome bands or tumor samples) into groups or
clusters, based on their similarity. Different (dis)similarity mea-
sures and clustering algorithms have been tested, and all brought
about equivalent results (a representative example is shown using
average linkage [unweighted pair group method with arithmetic
mean] and standard correlation as similarity metric). Holzman
and Kolker28 provide detailed information on explorative data
mining techniques (citing several good books that cover this
topic). Statistical analyses were performed with SPSS version 11
(SPSS Inc, Chicago, IL). Descriptive statistics based on 2 tests
were used to address the distribution of the genetic and clinical
parameters, and the International Neuroblastoma Pathology Clas-
sification (INPC) risk status in the three tumor clusters, or to
demonstrate the significant correlation between two parameters.
The Kaplan-Meier univariate survival analysis method and log-
rank test were used to estimate overall survival and event-free
survival. A stepwise Cox proportional hazards model (successive
exclusion of nonsignificant covariates with P .05) was applied to
test the independent significant influence of different genetic and
clinical parameters on patient outcome. Verification of the pro-
portional hazards assumption (stating that a particular covariate
should be proportionally related to the baseline hazard) was done
by inspecting the log-minus-log plot of the survival function.
Nonparametric Mann-Whitney testing was used to compare the
age at diagnosis between the different genetic subgroups.
Definition of Genetic Aberrations in
Statistical Analyses
The chromosome 17 status was defined as partial chromo-
some 17q gain (unbalanced gain of 17q relative to 17p), whole
chromosome 17 gain (an entire extra chromosome 17 relative to
ploidy), or normal (no gain of chromosome 17q material relative
to ploidy). Chromosome 1q gain was defined as partial 1q gain
relative to ploidy (irrespective of chromosome 1p status). The
term “deletion” was only used for tumor samples with partial loss
of a chromosome (eg, 11q deletion, in contrast to whole chromo-
some 11 loss). A normal chromosome arm status therefore indi-
cated absence of deletion (either no aberration or a numerical
change). The presence of either one of the following three genetic
defects (MYCN amplification or deletion of 1p or 11q) is referred
to as a positive amplification/deletion status (as opposed to a
negative amplification/deletion status, indicating a MYCN single
copy number and intact chromosomes 1 and 11).
RESULTS
Explorative and statistical analyses were applied to whole
genome chromosome status aberration information ob-
tained by CGH of 231 primary untreated neuroblastoma
tumors (see Materials and Methods). The median age at
time of diagnosis of these patients was 19.0 months. The
median follow-up time for survivors was 42.8 months (in-
terquartile range, 20.0 to 70.8). Of the 231 tumors, 88 were
from infants younger than 1 year, and 143 were from chil-
dren older than 1 year. According to the criteria of the
International Neuroblastoma Staging System, 32 tumors
were classified as stage 1, 35 as stage 2, 31 as stage 3, 100 as
stage 4, and 33 as stage 4S.
Generation of a Band-Specific Aberration Matrix
For all selected cases, the aberrations identified by
CGH were described according to the ISCN (ISCN 1995)
guidelines and were combined with patient follow-up, age
at time of diagnosis, tumor stage, ploidy, and INPC risk
status information (Supplemental Table). The CGH-based
reverse in situ hybridization–annotated karyotype informa-
tion was parsed with the ISCN2matrix converter to a 393-
band aberration matrix suitable for further data mining,
containing the aberration status (lost, gained, amplified, or
normal) for each individual chromosome band.
Visualization of Independent Genetic Events
by PCA
A key feature of our proposed strategy for exploratory
CGH data mining is the identification of the relevant and
independent genetic events before further analysis. This is
of major importance, as different chromosome bands in the
generated aberration matrix do not represent independent
variables: there is a high probability that neighboring bands
display the same aberration status because they are linked to
the same genetic defect (or normal status). As a result,
genetic defects involving more bands have a higher weight
in pattern discovery. Therefore, the predominant pattern
will be dictated by the chromosome(s) (arms) containing
the highest number of bands (for example, see the cluster-
ing of the neuroblastoma cases on the Progenetix23 Web
site, where chromosome 7 clearly has the highest weight). In
contrast, genetic defects represent independent single
events and should have equal weight, irrespective of the
number of bands involved in the particular aberration.
To achieve this goal, we applied PCA to the 393-band
aberration matrix for the 231 tumor samples. On projection
of the 393 chromosome bands on the first two principal
components, a clear picture of the chromosomal changes in
neuroblastoma tumorigenesis emerges, with losses in the
bottom left part, and gains in the upper right part of the
projection (Fig 1). The PCA algorithm succeeds in grouping
bands from the same chromosome or chromosome arm
together, solely based on the aberration status of each band
in the panel of tumors. It is also apparent from Figure 1 that
some chromosomes are split into one or more band clus-
ters, indicating that different regions in these chromosomes
display different aberrations patterns in the tumor panel.
In keeping with the PCA method, bands that cluster
further away from the origin explain more variance and
therefore represent significant alterations (eg, 2p23pter
amplification, 17q gain, and loss of 1p and 11q). In
contrast, bands closer to the center are not frequently
altered in neuroblastoma.
Vandesompele et al
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Hierarchical Cluster Analysis
From each band cluster in the PCA projection, one
band was selected to represent this chromosomal region. If
all bands from a single chromosome (except acrocentric
chromosomes) were grouped into one cluster, two bands
per chromosome were selected (one from each arm) to
exclude the possibility that a smaller proportion of tumors
could not be discriminated based on a possible differential
aberration status for the short and long arms. Accordingly,
the 393-band aberration matrix was reduced to a 45-band
matrix, representing independent variables. Hierarchical
clustering using different similarity or distance measures
and clustering algorithms yielded a series of equivalent ab-
erration patterns with three recurring distinct tumor clus-
ters. A representative example, including visualization of
the individual clusters on separate ideogram charts, is
shown in Figures 2A and B.
Cluster 1 contains 94 tumors with predominantly nu-
merical aberrations (typical gains of chromosomes 6, 7, and
17, and losses of chromosomes 3, 4, 11, and 14). The other
clusters are both characterized by structural chromosome
aberrations, such as partial 17q gain, 11q deletion, and to a
lesser extent, 3p deletion in the 45 cases of cluster 2; and
partial 17q gain, MYCN amplification, 1p deletion, and to a
lesser extent, 1q gain in the 74 cases from cluster 3. More
than 92% of all tumors fall into these three genetic sub-
groups. The remaining tumors are mainly characterized by
absence of recurrent genetic aberrations.
Genetic Subgroups in Relation to
Clinical Variables
Table 1 presents the relationship between clinical, ge-
netic, and histopathologic features and the three major
genetic subgroups as evidenced from hierarchical cluster
analysis. Tumor stage (1, 2, and 4S combined v 3 or 4); age
at time of diagnosis; ploidy; INPC risk status; MYCN copy
number; and chromosome 1p, 1q, 3p, 11q, and 17q status
are significantly nonrandomly distributed in the three clus-
ters (P .039 to P .0001). For none of the other regions
for which frequent loss has been reported (4p, 9p, 14q, 16p,
or 18q) could a significant association be demonstrated
with any of the clusters (P .1).
While patients from cluster 1 are clearly diagnosed at a
younger age compared with patients from cluster 2 or 3
(P  .0001), there is also a significant difference between
clusters 2 and 3 (P  .0078; Table 2). The cases with 3p
deletion seem to be partially responsible for the older age at
diagnosis in cluster 2, as within this cluster, tumors with loss
of 3p have a older age at diagnosis compared with 3p-intact
cases (median age, 60.5 v 39.0 months; P .027).
In keeping with the previously mentioned nonrandom
distribution of several parameters within the three genetic
subgroups, the Kaplan-Meier overall survival estimates are
significantly different between clusters 1 and 2 or clusters 1
and 3 (P  .0001), while no difference was found between
clusters 2 and 3 (P .62; Fig 2C).
Univariate Survival Analysis
To determine which parameters contribute to progno-
sis, we first tested each variable in a univariate Kaplan-
Meier survival analysis of all 231 patients (Table 3; Figs 3A
and B). Tumor stage, age at diagnosis, ploidy, INPC risk
status, MYCN gene copy number, and chromosome 1p, 1q,
11q, and 17q status are all significantly associated with
overall and (most often also) event-free survival.
Fig 1. Principal component analysis of
copy number information for 393 chromo-
some bands in 231 neuroblastoma tumors.
Projection of the chromosome bands on
the first two principal components (ex-
plaining 42.7% variance) delineates chro-
mosomal regions that are relevant to
neuroblastoma tumorigenesis.
Mining of Neuroblastoma CGH Data
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Besides confirmation of known significant parameters
in univariate survival analysis, this study demonstrated for
the first time that a normal chromosome 17 status is asso-
ciated with a poor prognosis. Losses of 3p, as well as losses of
other regions (4p, 9p, 14q, 16p, or 18q) have no predictive
power (P .1; data not shown).
Multivariate Survival Analysis
To identify which parameters that showed significant
predictive power in univariate analysis are independently
correlated to patient outcome, an initial stepwise Cox pro-
portional hazards procedure was applied to all 231 cases
incorporating clinical and genetic parameters that were
available for all samples. Age and the status of MYCN, 1p,
1q, and 11q were excluded from the final model of overall
survival probability (P .81, P .38, P .11, P .14, and
P .87, respectively). The remaining predictors for adverse
outcome were tumor stage 3 (hazard ratio, 2.66; 95% CI,
1.05 to 6.74; P  .039), tumor stage 4 (hazard ratio, 4.63;
95% CI, 2.06 to 10.38; P .00020), normal chromosome 17
status (hazard ratio, 3.19; 95% CI, 1.22 to 8.32; P  .018),
and partial 17q gain (hazard ratio, 3.82; 95% CI, 1.64 to
8.90; P .0019).
When the Cox proportional hazards procedure was ap-
plied to model event-free survival probability, only a normal
Fig 2. Delineation of three distinct clinicogenetic subgroups by (A) hierarchical clustering (green: gain; red: loss; dark green: amplification); (B) ideogram-based
representation of chromosomal gains and losses (same color legend as in A); and (C) Kaplan-Meier overall survival analysis (5-year estimates  SE, in months).
Vandesompele et al
2284 JOURNAL OF CLINICAL ONCOLOGY
Copyright © 2005 by the American Society of Clinical Oncology. All rights reserved. 
Downloaded from www.jco.org on March 31, 2005 . For personal use only. No other uses without permission. 
chromosome 17 status (hazard ratio, 4.80; 95% CI, 2.39 to
9.61; P  .0001) and partial chromosome 17q gain (hazard
ratio, 5.66; 95% CI, 3.26 to 9.82; P  .0001) remained inde-
pendent significant predictors for adverse prognosis.
No Cox regression model could be tested taking both
INPC risk status and ploidy into account, as only 18 cases
for which both these parameters were determined were
available. When tested separately (in conjunction with the
other clinical and genetic parameters), ploidy had no inde-
pendent predictive value, while the INPC risk status showed
only marginal significance (P  .12 for retention and
P .046 for removal of this parameter in the model). Please
note that these conclusions should be handled with care, as
ploidy and INPC information was available for only 26%
and 33% of the cases, respectively.
Stratified Survival Analyses for Chromosome 17
Status or Tumor Stage
Multivariate analysis indicated that chromosome 17
status and tumor stage are the only significant independent
single parameters to model patient outcome. To determine
which parameters further contribute to survival within
Table 1. Distribution of Clinical, Genetic, and Histopathologic Parameters in the Three Clinicogenetic Subgroups
Parameters
Cluster 1 Cluster 2 Cluster 3
P 
No. of
Patients
% Within
Each Cluster
No. of
Patients
% Within
Each Cluster
No. of
Patients
% Within
Each Cluster
Tumor stage
1, 2, 4S 72 77 7 16 14 19  .0001
3 13 14 2 4 16 22
4 9 9 36 80 44 59
Age, years
 1 60 64 5 11 19 26  .0001
 1 34 36 40 89 55 74
MYCN gene
Single copy 94 100 45 100 23 31  .0001
Amplified 0 0 0 0 51 69
Chromosome 1p
Normal 90 96 40 89 23 31  .0001
Deleted 4 4 5 11 51 69
Chromosome 1q
Normal 89 95 35 78 52 70 .00012
Gain 5 5 10 22 22 30
Chromosome 3p
Normal 87 93 33 73 70 95 .00053
Deleted 7 7 12 27 4 5
Chromosome 11q
Normal 85 90 15 33 68 92  .0001
Deleted 9 10 30 67 6 8
Chromosome 17q
Normal 0 0 2 4 11 15  .0001
Whole chromosome gain 84 89 6 13 7 9
Partial 17q gain 10 11 37 82 56 76
Ploidy†
Near-triploid 21 68 2 33 0 0  .0001
Near-diploid/tetraploid 10 32 4 67 19 100
INPC risk status†
Favorable 11 33 1 11 3 10 .039
Unfavorable 22 67 8 89 26 90
P values calculated with the 2 test.
†Not available for all cases.
Table 2. Age at Time of Diagnosis
Cluster
No. of
Patients
Mean
Age
Median
Age
Interquartile
Range P 
1 94 14.3 9.0 4.0-16.3
2 45 47.2 41.0 26.4-62.5
3 74 34.4 26.0 11.0-52.0
Comparison
1 v 2 .0001
1 v 3 .0001
2 v 3 .0078
NOTE. Age is given in months.
Mann-Whitney two-independent-samples test.
Mining of Neuroblastoma CGH Data
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specific subgroups, we performed stratified subgroup anal-
yses (Table 4; Figs 4A to D).
Within the favorable-stage tumors (1, 2, or 4S), the
following parameters were associated with lower overall
survival probability (P values 0.0001): MYCN amplifica-
tion, 1p deletion, normal chromosome 17 status, and par-
tial 17q gain. Again, it is important to note that both a
normal chromosome 17 status as well as a partial 17q
gain identify low-stage patients with increased risk. Pa-
tients with a low-stage tumor displaying whole chromo-
some 17 gain have a 100% survival probability (Fig 4C).
For stage 3 or 4 tumors, no further significant parameters
could be discriminated.
Within the group of patients whose tumor showed
whole chromosome 17 gain, the following parameters were
associated with lower overall survival: 11q loss (P .0019),
1q gain (P  .046), age older than 1 year at diagnosis
(P  .0001), and tumor stage 3 (P  .0001) and stage 4
(P  .0001). In line with the stage-stratified survival esti-
mates, patients with whole chromosome 17 gain diagnosed
prior to age 1 year (62 of 97 patients) or with tumors
belonging to stages 1, 2, or 4S (76 of 97 patients) displayed a
100% overall survival (Figs 4A and B).
Within the group of patients whose tumors showed a
normal chromosome 17 status (in a background of other
genetic defects), borderline significant association with ad-
verse outcome could be demonstrated for 1q gain or 1p
deletion (P  .039 and P  .032, respectively). Within the
subgroup of high-risk tumors with partial 17q gain, only
stage 4 had additional predictive power (P .022; Fig 4D).
As the MYCN status is currently the only genetic pa-
rameter that is incorporated in therapy stratification, we
tested whether the chromosome 17 status allowed further
stratification in the group of MYCN-amplified and single-
copy tumors. A normal chromosome 17 status or a partial
17q gain are both significantly associated with decreased
Table 3. Univariate Kaplan-Meier Survival Estimates
Parameters
No. of
Patients
5-Year OS
OS P 
5-Year EFS
EFS P OS SE EFS SE
Tumor stage
1, 2, 4S 100 92.32 2.80 72.25 5.08
3 31 63.62 9.31 .0003 49.22 11.12 .058
4 100 30.73 5.28  .0001 27.81 5.10  .0001
Age
 1 88 85.55 4.12 70.55 5.74
 1 143 46.87 4.67  .0001 37.00 4.68  .0001
MYCN gene
Single copy 180 68.97 3.86 55.77 4.41
Amplified 51 36.69 7.29  .0001 31.20 6.95 .0008
Chromosome 1p
Normal 167 70.35 3.98 58.12 4.57
Deleted 64 39.36 6.66  .0001 29.64 6.51  .0001
Chromosome 1q
Normal 190 67.30 3.73 56.62 4.14
Gain 41 37.53 8.21 .0013 24.39 7.71 .0018
Chromosome 3p
Normal 205 62.97 3.75 51.77 4.07
Deleted 26 52.50 10.48 .21 37.27 10.35 .14
Chromosome 11q
Normal 182 66.10 3.88 55.56 4.17
Deleted 49 44.83 8.04 .0055 29.91 8.43 .022
Chromosome 17q
Whole chromosome gain 97 89.96 3.42 80.39 4.56
Normal 27 56.30 10.33  .0001 33.63 10.98  .0001
Partial 17q gain 107 38.07 5.27  .0001 26.36 5.36  .0001
Ploidy
Near-triploid 24 95.83 4.08 61.00 11.37
Near-diploid/tetraploid 37 61.00 8.63 .018 50.91 8.66 .24
INPC risk status
Favorable 15 93.33 6.44 77.04 11.97
Unfavorable 62 55.96 7.03 .013 42.57 7.70 .036
Abbreviations: OS, overall survival; EFS, event-free survival.
Log-rank statistic, for each variable with respect to the first variable (eg, stage 3 v stages 1, 2, and 4S).
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survival probability (P  .001) of patients with a MYCN
nonamplified neuroblastoma. In contrast, chromosome 17
status allows no further stratification in MYCN-amplified
tumors because MYCN amplification is almost invariably
associated with a normal chromosome 17 or partial chro-
mosome 17q gain status (there is only one tumor with
MYCN-amplification in combination with whole chromo-
some 17 gain).
Development of a New Regression Model to
Predict Outcome in Neuroblastoma
In the previous paragraphs, all patterns for chromo-
some 17 are considered as separate entities (whole chromo-
some gain, partial 17q gain, and a normal status), whereby it
is demonstrated that a normal chromosome 17 status (just
like partial 17q gain) is a significant predictor for poor
outcome. However, up till now, no other study has consid-
ered neuroblastoma with normal chromosome 17 status as
a separate entity. Most studies determined whether the
tumor showed partial chromosome 17 gain or not (hence
grouping together whole chromosome gain and a normal
chromosome 17 status, hereafter referred to as “conven-
tional dichotomization”). Because the fraction of tumors
with a normal chromosome 17 status is relatively low (ap-
proximately 12% in the present study), conventional di-
chotomization still results in a highly significant association
of chromosome 17 status with survival probability. Here,
we propose a new improved dichotomization, whereby tu-
mors with a normal chromosome 17 status are grouped
together with those characterized by a partial 17q gain, and,
as such, are compared as one entity with tumors with whole
chromosome 17 gain. Cox proportional hazards regression
not only demonstrated a greater relative risk ratio for the
improved versus conventional dichotomization (8.56 v
4.55), but also indicated that when both dichotomization
strategies were analyzed together, only the improved one
retained independent predictive power.
The findings given in this section indicate that a whole
chromosome 17 gain status confers a good prognosis and is
the most important genetic parameter for a high survival
probability. While whole chromosome 17 gain is strongly
associated with a numerical aberration pattern, a normal
chromosome 17 and partial 17q gain status are almost al-
ways found in a background of other structural chromo-
some aberrations. To test whether the structural aberration
pattern itself (partial chromosome deletions or amplifica-
tions) is indicative of poor survival, we determined whether
patients whose tumor showed any structural chromosome
aberration had poorer outcomes compared with patients
whose tumor presented with numerical aberrations only. As
expected, a structural aberration pattern was a significant
predictor in univariate survival analyses (P .0001). Mul-
tivariate outcome prediction, however, could not attribute
independent prognostic power to a structural aberration
pattern. Further analyses indicated that a surprisingly high
fraction of tumors with whole chromosome 17 gain (45 of
97 tumors) also displayed one or more structural aberra-
tions (while it was expected that virtually all tumors [131 of
134] with a normal chromosome 17 status or partial 17q
gain would show a structural aberration pattern). Closer
inspection, however, revealed that only a minority of these
cases (11 of 97) presented with one of the three genetic
defects typically found in higher-stage aggressive tumors
(found in clusters 2 and 3; ie, MYCN amplification, 1p
deletion, or 11q deletion), suggesting that many of the
structural defects observed in conjunction with whole chro-
mosome 17 gain are nonfrequently occurring genetic
changes. This prompted us to determine whether the pres-
ence of either MYCN amplification or loss of 1p or 11q
Fig 3. Kaplan-Meier overall survival analysis (in months) of all cases divided by tumor stage (A) or chromosome 17 status (B) (Table 3).
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(hereafter referred to as a positive amplification/deletion
status; see Materials and Methods) could serve as a new
powerful and independent prognostic parameter. Indeed,
Cox multivariate survival analysis indicated that the ampli-
fication/deletion status (hazard ratio, 2.04; 95% CI, 1.06
to 3.91; P  .032), the improved chromosome 17 status
dichotomization (hazard ratio, 2.77; 95% CI, 1.14 to 6.72;
P  .025), and tumor stage (3 and 4 v 1, 2, and 4S; hazard
ratio, 3.49; 95% CI, 1.60 to 7.63; P .0017) were indepen-
dent predictors for adverse outcome. Table 5 gives an over-
view of the hazard ratios (relative to patients with a stage 1,
2, or 4S tumor showing whole chromosome 17 gain and
a negative amplification/deletion status) for patients stratified
according to previously mentioned independent outcome
predictors. Subsequent confirmatory analyses indicated that
the improved chromosome 17 status dichotomization in-
deed allowed further stratification in cases with a negative
(P  .0001) or positive (P  .052) amplification/deletion
status. Likewise, the amplification/deletion status parame-
ter also allowed further stratification within the cases with
Table 4. Stratified Kaplan-Meier Survival Estimates
Stratum and Factors
Patients 5-Year OS
OS P†No. No. Dead OS SE
Stage
1, 2, 4S
MYCN
Single copy 93 5 96.34 2.08
Amplification 7 4 42.86 18.70  .0001
Chromosome 1p
Normal 86 3 98.78 1.21
Deleted 14 6 57.14 13.23  .0001
Chromosome 17
Whole chromosome gain 76 0 100.00
Normal 8 4 41.67 20.48  .0001
Partial gain 16 5 75.00 10.83  .0001
3‡ 31 11 63.62 9.31
4‡ 100 59 30.73 5.28
Chromosome 17
Whole chromosome gain
Chromosome 11q
Normal 89 5 92.61 3.23
Deleted 8 3 62.50 17.12 .0019
Chromosome 1q
Normal 91 6 91.98 3.20
Gain 6 2 66.67 19.25 .046
Age at diagnosis, years
 1 62 0 100.00
 1 35 8 72.85 8.33 .0001
Stage
1, 2, 4S 76 0 100.00
3 11 3 70.71 14.29  .0001
4 10 5 45.00 17.43  .0001
Normal
Chromosome 1q
Normal 22 8 65.20 11.04
Gain 5 4 20.00 17.89 .039
Chromosome 1p
Normal 14 4 75.00 12.94
Deleted 13 8 38.46 13.49 .032
Partial 17q gain
Stages 1, 2, 4S 16 5 75.00 10.83
Stage 3 16 7 55.68 13.74 .088
Stage 4 75 47 26.13 5.71 .022
Abbreviation: OS, overall survival.
Listed are only those stratifying parameters with significant independent prognostic power according to multivariate regression (see Results), and only
those factors with significant univariate predictive power in each stratum.
†Log-rank statistic for each factor variable with respect to the first variable (eg, normal chromosome 17 status v whole chromosome 17 gain).
‡No significant factors.
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whole chromosome 17 gain (P .024), or either a normal
chromosome 17 status or partial 17q gain (P .016; Fig 5).
DISCUSSION
Deletion of the distal part of chromosome arm 1p and
amplification of the MYCN oncogene were the first genetic
markers of advanced-stage neuroblastoma recognized in
the initial cytogenetic investigations of this tumor. Subse-
quently, an array of other recurrent structural chromosome
aberrations was reported, and some were found to be asso-
ciated with patient outcome. However, it was not until the
advent of the whole genome scanning method CGH that a
global view on the genetic heterogeneity and the interrela-
tionship of the imbalances could be obtained. These studies
not only provided insights in the genetic basis underlying
the clinical variability associated with this childhood tumor,
but most importantly, provided clues about the existence of
two different genetic subgroups of advanced-stage unfavor-
able neuroblastomas, characterized by MYCN amplifica-
tion and loss of 11q, respectively.
Despite the wealth of information CGH brought about
with respect to identification of chromosomal regions of
consistent loss or gain, many publications suffer from a lack
of uniform data presentation and detailed aberration infor-
mation for the individual cases. As such, it has proven
impracticable or impossible to reanalyze data or pool case
results from different (often of relatively small sample size)
studies to strengthen conclusions or gain further insight
into the different aberration patterns or genetic subgroups
that might exist. To overcome this problem, a public repos-
itory for published CGH data in a format suitable for data
mining procedures has been initiated.23 Equipped with the
ability to convert analogous CGH profiles to a digitized data
mining– compatible format, we sought to apply common
bioinformatics algorithms to CGH-based chromosome
Fig 4. Stratified survival analysis of tumors presenting with whole chromosome (chr) 17 gain subdivided by (A) tumor stage or (B) age at diagnosis; (C)
favorable-stage tumors subdivided by chromosome 17 status; or (D) tumors with partial 17q gain subdivided by tumor stage (Table 4).
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aberration information, and performed for the first time a
comprehensive and in-depth analysis of genetic aberrations
occurring in the various neuroblastoma subtypes.
In the approach presented here, principal component
analysis was an important step toward unbiased delineation
of independent genetic events before explorative and statis-
tical analyses. Subsequent hierarchical clustering firmly es-
tablished the existence of three distinct genetic subgroups.
Interestingly, these three subgroups not only differ with
respect to their genomic aberration patterns, but are also
Table 5. Relative Risk Ratio for Neuroblastoma Patients Stratified for Stage, Chromosome 17, and Amplification/Deletion Status
Whole Chromosome 17 Gain Normal Chromosome 17 Status or Partial 17q Gain
No. of
Patients
No. of
Deceased 5-Year OS SE Hazard
No. of
Patients
No. of
Deceased 5-Year OS SE Hazard
Negative amplification/deletion status
stages 1, 2, 4S 70 0 100 1.00 9 2 88.89 10.48 2.77
stages 3, 4 16 5 63.48 13.34 3.49 19 8 46.23 13.34 9.66
Positive amplification/deletion status
stages 1, 2, 4S 6 0 100 2.04 15 7 60.00 12.65 5.64
stages 3, 4 5 3 40.00 21.91 7.12 91 54 32.48 5.53 19.68
Abbreviation: OS, overall survival.
Fig 5. Stratified survival analysis of cases presenting with a negative (A) or positive (B) amplification/deletion status subdivided by chromosome (chr) 17 status;
cases presenting with whole chromosome 17 gain (C) or normal chromosome 17 status/partial 17q gain (D) subdivided by amplification/deletion status.
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characterized through significantly different age at time of
diagnosis, tumor stage distribution, ploidy level, INPC risk
status, and survival probability. Cluster 1 represents pre-
dominantly near-triploid low-stage tumors with numerical
aberrations and favorable histology from infants (median
age at diagnosis, 9 months) with excellent outcome. Cluster
2 contains predominantly near-diploid/tetraploid stage 4
tumors with unfavorable histology, partial 17q gain, and
11q loss, often in association with loss of 3p. These patients
present with the oldest age at diagnosis (median age, 41
months) and have a poor overall 5-year survival of ap-
proximately 40%, which is similar to that of patients
from cluster 3 (median age, 26 months), who present
with near-diploid/tetraploid high stage tumors display-
ing unfavorable histology and partial 17q gain, loss of 1p,
and MYCN amplification.
The difference in age at diagnosis between high-stage
clusters 2 and 3 may be explained by a difference in growth
rate and/or the need for an additional genetic defect in a
cluster 2 tumor to become clinically manifest (as suggested
by a large proportion of 3p loss in cluster 2, associated with
an older age at diagnosis). This indicates that clusters 2 and
3 are clinically distinct and might behave differently, which
suggests discrimination between those tumor subtypes in
future therapeutic strategies.
While acknowledging the limitations of explorative
cluster analysis (in that the answer is not absolute, and
that different distance measures and cluster algorithms
may result in differences between the generated patterns
or clusters), we believe that the recurring patterns we
observed, in addition to the significant nonrandom asso-
ciation of relevant neuroblastoma parameters to the ob-
served clusters, render confidence to the presented
clusters, delineating three major different clinicogenetic
subgroups in neuroblastoma.
Although the existence of clinicogenetic subgroups has
been proposed in previous studies, these conclusions were
not based on in-depth analysis owing to various limitations
such as sample size, tumor stage distribution, or nonin-
clusion of all relevant genetic aberrations.5,10,20,29 In
contrast, this study provides an unbiased and compre-
hensive assessment of the subgroups based on a large
series of tumor samples belonging to all stages, and based
on all relevant genetic, histopathologic, and clinical in-
formation. Furthermore, our finding of 3p loss as a hall-
mark of older age at diagnosis provides additional insight
into the series of genetic events leading to a subtype of
aggressive neuroblastoma.
To determine which of the individual parameters inde-
pendently contribute to survival probability, stratified uni-
variate and multivariate analyses were performed. Both
analyses demonstrated that chromosome 17 status and tu-
mor stage are the only significant independent predictors
for patient outcome, corroborating previous studies11,29-31
and emphasizing the need to include at least tumor stage
and chromosome 17 status in future multivariate evalua-
tions of prognostic parameters. As many of the cases in this
article were also compiled in an even larger multicenter
study (reporting only on chromosome 1 and 17, MYCN
status, and ploidy), our conclusion about the prognostic
significance of chromosome 17 is not surprising. However,
more importantly, we obtained new information regarding
patients with a normal chromosome 17 status. Please bear
in mind that these tumors always displayed other cytoge-
netic aberrations (Supplemental Table), as we excluded
tumors with no detectable changes (see Materials and
Methods). We were able to demonstrate that a normal
chromosome 17 status (in conjunction with other defects)
is an independent marker, and that patients with these
tumors had an equally adverse outcome compared with
those with partial chromosome 17q gain, a finding that is
particularly true for favorable-stage tumors 1, 2, and 4S. In
other words, a normal chromosome 17 status or partial
chromosome 17q gain identify a new subgroup of
increased-risk patients with presumed favorable-stage tu-
mors. This finding may have important clinical conse-
quences with respect to proper treatment and assessment of
new therapeutic protocols. It is important to note that we
could not confirm the recently reported adverse prognostic
power of 3p or 11q loss in localized and stage 4S tumors.32
Taken together, these analyses indicate that the pres-
ence of an extra chromosome 17 (often in a background of
other numerical aberrations) is the most important inde-
pendent genetic indicator for excellent patient outcome,
and suggest that these tumors represent a separate biologic
entity of favorable neuroblastomas.
A second important new observation, in line with the
previous statement, was the identification of a specific sur-
vivor signature for children with neuroblastoma. Within
the subgroup of tumors with whole chromosome 17 gain,
tumor stage and age at diagnosis seem to have additional
predictive power: the group of patients with either a favorable-
stage tumor (stages 1, 2, and 4S) showing whole chromosome
17 gain, or a tumor with whole chromosome 17 gain diag-
nosed before age 1 year, show a 100% overall survival (Fig 4).
Considering that whole chromosome 17 gain is strongly asso-
ciated with near-triploidy, the above findings are in keeping
with the report that ploidy is a strong prognostic factor for
children younger than 1 year at diagnosis.3
The fact that the MYCN status as a standard marker for
neuroblastoma therapy stratification drops out of the mul-
tivariate analysis is not unexpected, nor contrary to pub-
lished data. As in many other reports based on univariate
analysis, MYCN amplification is also a strong predictor for
adverse outcome in this study. However, when other ge-
netic, clinical, or histopathologic parameters are taken into
account (multivariate analysis), MYCN status no longer has
independent predictive power, corroborating published
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reports.11,29 This can be explained by the strong association
of MYCN-amplification with other prognostic factors (eg,
stage 4 and gain of 17q) that occur more frequently, and
hence, can predict outcome for a larger proportion of pa-
tients. The fact that Cox proportional hazards modeling
attributes independent prognostic value to those parame-
ters that can predict an adverse outcome for as many pa-
tients as possible also explains why other genetic parameters
that have univariate prognostic value (such as loss of 1p and
11q) drop out of the multivariate model when chromosome
17 status is included. This prompted us to investigate
whether the combination of MYCN status and 1p or 11
deletion could serve as a new powerful independent predic-
tor (besides chromosome 17 status) in multivariate survival
analysis. Indeed, we could develop a new regression model
that incorporates tumor stage (3 and 4 combined v 1, 2, and
4S); chromosome 17 status (whole chromosome gain v
combined partial gain or normal chromosome status); and
the combined status of MYCN, 1p, and 11q (amplification/
deletion status). This new three-parametric model can pre-
dict patient outcome more accurately than any other tested
model incorporating one or more of the available parame-
ters (as evidenced by the relative risk ratio and overall score
of the model). It will prove interesting to validate this model
in other large cohorts of uniformly treated patients for
whom all clinical, genetic, and histopathologic parameters
are available. Again, the model demonstrates that in addi-
tion to the current incorporation of the MYCN status in
therapy stratification, chromosome 17 status and preferably
also chromosome 1 and 11 status should be routinely as-
sessed and taken into consideration in the evaluation of
clinical trials and possible future therapeutic stratifications.
While many studies have confirmed the initial report on
the clinical significance of unbalanced 17q gain in neuroblas-
toma,11 a recent fluorescence in-situ hybridization (FISH)
–based study failed to attribute prognostic value to 17q gain.33
Our observation that a normal chromosome 17 status is also a
strong predictor for adverse outcome, and that in the refer-
enced FISH study, conventional dichotomization is used
(hence grouping together favorable tumors with whole chro-
mosome 17 gain and unfavorable tumors with a normal chro-
mosome 17 status) might (partly) explain why in this specific
study, 17q gain was not recognized as a prognostic marker,
especially if a relatively high proportion of cases with a true
normal chromosome 17 status was included. The discrepant
results might also be explained by the particular method that is
used to score chromosome 17 gain. Most studies attributing
prognostic value to the chromosome 17 aberration status re-
lied entirely or predominantly on CGH. The study that failed
to confirm the chromosome 17 findings is based exclusively on
FISH interpretation of 17q copy number gain. Preliminary
data in our laboratory, based on FISH analyses, indicate large
intratumoral heterogeneity of chromosome 17 copy numbers
and aberration status (whole chromosome gain and partial
gain present in the same tumor), complicating unequivocal
interpretation. Multicolor interphase FISH and (microarray-
based) CGH side-by-side comparisons are ongoing to assess
concordance between these detection methods (data will be
published elsewhere).
The present study is also relevant in light of current
efforts of tumor subgroup classification based on transcrip-
tome profiling using oligonucleotide or cDNA microarrays.
These methods are relatively expensive and require signifi-
cant amounts of high-quality RNA. Assessment of genetic
defects at the DNA level with strong diagnostic and prog-
nostic relevance may provide a valuable alternative, as dem-
onstrated by other studies.34-37 In this context, the recent
report indicating the superiority of genomic aberration pat-
terns with respect to tumor subtype identification com-
pared with expression profiles, is of particular interest.38
Another important feature of our proposed scheme for
data handling is its applicability to promising new whole
genome profiling strategies such as Serial Analysis of Gene
Expression–based digital karyotyping39 and microarray-
based CGH in which metaphases have been replaced by ar-
rayed genomic BAC clones,40,41 cDNA transcripts,42 or
oligonucleotides.43,44 These new technologies not only offer a
significant increase in resolution, but are also adaptable to
automation, leading to higher throughput. Hence, going from
a cytogenetic to a molecular analysis level, it is expected that
new aberrations will be identified, hopefully speeding up the
discovery of molecular targets for the development of en-
hanced therapeutic approaches.
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Supplemental Table: Clinical, Genetic, and Histopathologic Parameters and CGH Aberrations for 231 Primary Untreated Neuroblastomas
Identifier Clustera Stage Ageb Eventc EFSd Survivale OSf Ploidyg INPCh CGH Aberrations
NBL-Meta-1 1 4 95 1 32 1 32 — U rev ish enh(7p21p22, 7q21q36, 8p, 17q12q25) dim(2p24p25,
3p14p26, 4p, 11q14q25, X)
NBL-Meta-2 2 4 66 1 20 1 20 — U rev ish enh(1q22q25, 7q22, 7q32q36, 12q23q24, 17q12q25, 18)
dim(9p13p24, 11q14q25, Y)
NBL-Meta-3 3 4 69 1 6 1 14 — U rev ish amp(2p23p24)
NBL-Meta-4 3 4 23 1 19 0 58 — U rev ish enh(2p12p22, 2p25, 17q11q25) dim(1p32p36)
amp(2p23p24)
NBL-Meta-6 1 2 12 0 78 0 78 — — rev ish enh(7, 13, 17, 18) dim(3, 4p, 9p24q32, 11, 14, X)
NBL-Meta-7 3 4 14 0 58 0 58 — F rev ish enh(3q13q29, 17q11q25, 19p) dim(1p32p36, 15q11q13,
19q) amp(2p23p24)
NBL-Meta-8 1 2 5 0 55 0 55 — F rev ish enh(6p, 6q24q27, 7, 8p, 8q24, 17) dim(4, 14, 16q, X)
NBL-Meta-9 1 4S 6 0 54 0 54 — F rev ish enh(1p21q44, 2p25q21, 6p25q13, 6q24q27, 7, 12, 17, 22)
dim(2q23q37, 3, 4, 5, 8, 10p13p15, 11p, 11q14q25, 14,
15q11q22, 18, 21, X)
NBL-Meta-11 1 1 4 0 49 0 49 — F rev ish enh(2, 7, 12, 17) dim(3, 4, 6, 8, 9p, 10, 11, 13, 14, 15, 18)
NBL-Meta-12 3 4 58 1 13 1 15 — — rev ish enh(1p31q44, 2p22q37, 2p25, 8q24, 17q11q25)
dim(1p32p36, 3, 9, 11p12p14, 11q14q21, 13, 14, 15q11q15,
21q22) amp(2p23p24)
NBL-Meta-13 3 4 66 0 46 0 46 — U rev ish enh(17q11q25) dim(X) amp(2p23p24, 10p13p14,
10q24q25)
NBL-Meta-14 2 1 17 0 117 0 117 tri U rev ish enh(7, 8, 17, 18, X)
NBL-Meta-15 1 1 10 0 60 0 60 — — rev ish enh(6, 7, 8, 13, 17, 20, 22) dim(11, 12, 14)
NBL-Meta-16 2 1 36 0 67 0 67 tri — rev ish enh(1q, 5q23q35, 17) dim(2p23p25, 2q33q37, 3p21p26,
3q24q29, 4p15p16, 4q, 10q23q26, 11q14q25, 14q31q32)
NBL-Meta-17 1 1 12 0 71 0 71 di U rev ish enh(6, 7, 17, 19)
NBL-Meta-18 1 1 7 1 6 0 108 — — rev ish enh(7, 17, 19p) dim(9p)
NBL-Meta-19 1 1 0.1 0 119 0 119 — — rev ish enh(2, 6, 7, 12, 13, 17, 18)
NBL-Meta-21 1 2 11 0 88 0 88 tri U rev ish enh(2, 6, 7, 12, 17, 18, 22) dim(4, 9, 16, X)
NBL-Meta-22 1 2 3 0 54 0 54 — — rev ish enh(6, 9, 12, 17, 18, 20, 22) dim(4, X)
NBL-Meta-23 1 2 1 0 127 0 127 — — rev ish enh(6, 7, 17, 18p11q21, 19, 22) dim(3p22p26)
NBL-Meta-24 1 4S 3 0 108 0 108 — F rev ish enh(2p14p25, 17, 18p11q21, 19p13q13) dim(8q23q24,
11p14p15, 11q22q25, 14q32, 16q13q24)
NBL-Meta-25 4 4S 3 1 51 1 74 tri U rev ish enh(7, 18) dim(21, Xq22q28)
NBL-Meta-26 3 4 2 1 1.5 1 1.5 tetra — rev ish enh(2p22p25, 15q25q26, 17q22q25) dim(1p32p36, 9,
14q21q32, 19, 21q22, 22)
NBL-Meta-27 1 3 20 1 19 1 21 — U rev ish enh(1q, 12, 17, 19)
NBL-Meta-28 1 3 36 0 131 0 131 — — rev ish enh(16p, 17, 18p11q11, 19) dim(3p22p26, 3q26q29, 14)
NBL-Meta-29 1 3 8 0 66 0 66 tri U rev ish enh(6, 7, 8, 13, 17, 18) dim(14, 16q, X)
NBL-Meta-30 3 3 25 0 42.5 0 42.5 di — rev ish enh(12q13q24) dim(1p22p36) amp(2p23p24)
NBL-Meta-31 4 2 10 1 20 0 149 — — rev ish enh(5q14q22, 4q21q31) dim(14, 17p, 19, 22)
NBL-Meta-32 3 3 20 0 46 0 83 tetra — rev ish enh(2p23p24, 17q22q25) dim(1p22p36, 10)
NBL-Meta-33 3 4 101 1 19 1 19 — U rev ish enh(1q12q32, 2p23p25, 5q31q35, 6, 7, 11p, 13, 16p, 17,
18, 20, 21) dim(11q22q25)
NBL-Meta-34 2 4 31 1 8 0 111 — — rev ish enh(1q, 1p36, 5q31q35, 11q13, 12q21q24, 13, 17q)
dim(3p22p26, 11q14q25, 14q22q32)
NBL-Meta-35 2 4 65 0 40 0 40 — — rev ish enh(7, 11q13, 17, 18) dim(3p14p26, 4p, 11q14q25, 20p)
NBL-Meta-37 1 4 47 1 24 1 36 — — rev ish enh(17, 19) dim(X)
NBL-Meta-38 3 4 57 1 24 1 25 di U rev ish enh(1q, 11q13, 17q, 7, 12) dim(1p, 11q14q25, 3, 10, 15)
amp(2p23p24)
NBL-Meta-39 1 4 63 1 3 1 3 — U rev ish enh(2p11p15, 5p15q11, 12q22q24, 6, 7, 15, 16, 17,
18p11q21, 22) dim(2q, 4, 8, 9, 11p15q12, 11q14q25, 14, 21,
X) amp(11q13)
NBL-Meta-40 2 4 57 1 13 1 21 di U rev ish enh(1q, 7p15p21, 17q) dim(2p23p25, 3p21p26,
11q14q23, 14q24q32)
NBL-Meta-41 2 4 49 1 15 1 20 — — rev ish enh(17q22q25) dim(1q42q44)
NBL-Meta-42 2 4 41 0 90 0 90 di F rev ish enh(17q21q25)
NBL-Meta-43 3 4 32 1 18 1 24 — — rev ish enh(2p, 17q22q25) dim(1p32p36, 3p14p26, 14q32, 17p,
18q22q23, 9)
NBL-Meta-44 3 4 17 0 116 0 116 tetra — rev ish enh(17q22q25) dim(1p33p36, 9p21p24) amp(2p23p24)
NBL-Meta-45 3 4 35 0 66 0 66 tetra — rev ish dim(1p31p36, 9p21p24) amp(2p23p24)
NBL-Meta-46 2 4 32 0 104 0 104 — — rev ish enh(1q23q32, 7q21q36, 17q22q25) dim(1q42q44, 5p, 8p,
10p, 11q14q25)
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Identifier Clustera Stage Ageb Eventc EFSd Survivale OSf Ploidyg INPCh CGH Aberrations
NBL-Meta-47 3 4 178 1 13 0 27.5 di — rev ish enh(1q32q44, 11q14q25, 22) dim(1p21p36, 3p22p26,
19q13) amp(2p23p24)
NBL-Meta-48 3 4 19 0 80 0 80 di — rev ish enh(2p25, 17q23q25) dim(1p31p36) amp(2p23p24)
NBL-Meta-49 3 4 33.5 0 86 0 86 di — rev ish enh(2p23p25, 2q22q37, 5q14q23, 17q, 18q12q23, 7, 12,
22q13)
NBL-Meta-51 1 1 4 1 8 0 11 — — rev ish enh(1, 2, 5p, 5q15q23, 6, 7, 12, 13q13q34, 17) dim(3, 4,
10, 11, 14, 15, 16)
NBL-Meta-52 1 1 17 0 5 0 5 — — rev ish enh(2p12p21, 2p23p25, 5, 7, 13, 17, 18) dim(3, 4, 14)
NBL-Meta-53 1 1 19 0 10 0 10 — U rev ish enh(6, 7, 13q21q34, 17, 18, 22) dim(3p21p26, 4, 10,
14q12q32, 15q21q26, 21)
NBL-Meta-54 2 1 9 0 9 0 9 — U rev ish enh(1p, 17, 18) dim(4, 8, 10, 14)
NBL-Meta-55 1 1 4 0 12 0 12 — U rev ish enh(7, 12, 17) dim(4, 21)
NBL-Meta-56 1 1 15 0 15 0 15 — — rev ish enh(5, 6, 7, 12, 17, 18q) dim(3, 4, 14, 22)
NBL-Meta-57 1 1 10 0 11 0 11 — — rev ish enh(1, 2, 5, 7, 12, 17, 19, 20, 22) dim(3, 4, 6, 8, 13, 14,
15q21q26, 18, 21)
NBL-Meta-58 1 2 26 0 21 0 21 — U rev ish enh(7, 13, 17, 18) dim(4)
NBL-Meta-59 3 3 96 0 14 0 14 — U rev ish enh(1q21q44, 2p23q37, 17q23q25, 18) dim(1p22p36, 3)
amp(2p24p25)
NBL-Meta-60 1 3 11 0 15 0 15 — U rev ish enh(7, 17q22q25) dim(4, 11q22q25)
NBL-Meta-61 3 3 31 1 9 0 43 — U rev ish enh(2p15p22, 17q22q25) dim(1p31p36) amp(2p23p24)
NBL-Meta-62 3 3 12 0 19 0 19 — U rev ish enh(12q22q24) dim(1p34p36, 8p22p23, 16) amp(2p24p25,
2p21)
NBL-Meta-63 3 3 48 0 41 0 41 — U rev ish enh(1p34q44, 2q23q37, 4, 12q21, 12q24, 17q22q25)
dim(1p35p36, 15, 19, 20q, 22) amp(2p23p25)
NBL-Meta-64 3 3 23 1 1 1 1 — U rev ish enh(1p31q44, 2p11p21, 2q, 4, 13q32q34, 17q22q25, 18q)
dim(1p32p36, 15q21q26, 20, 22) amp(2p23p25)
NBL-Meta-65 3 3 59 0 7 0 7 — U rev ish enh(1, 2q, 7, 17q22q25, 21) dim(8p22p23, 14q12q32,
15q15q26, 17p12p13, 19) amp(2p23p25)
NBL-Meta-66 2 3 59 1 59 0 82 — U rev ish enh(1q21q32, 7, 12q22q24, 17q22q25, 18q)
dim(11q14q25)
NBL-Meta-67 3 3 52 1 18 1 18 — — rev ish enh(1q, 2p21q37, 3, 7, 9q32q34, 17q22q25, 18)
dim(10q23q26) amp(2p23p25)
NBL-Meta-68 3 3 52 1 9 1 18 — — rev ish enh(1q, 2p21q37, 3, 7, 9q32q34, 17q22q25, 18)
dim(10q23q26) amp(2p23p25)
NBL-Meta-69 1 3 19 0 88 0 88 — U rev ish enh(1, 2, 7, 13, 17, 18) dim(3, 4, 9)
NBL-Meta-70 3 4 19 1 8 1 8 — — rev ish enh(17q21q25) dim(1p34p36) amp(2p23p25)
NBL-Meta-71 4 4 38 1 8 1 8 — — rev ish enh(11p, 17q22q25) dim(3p21p26, 11q21q25)
amp(16q21q24)
NBL-Meta-73 3 4 122 0 13 0 13 — U rev ish enh(1p12p22, 1q, 2p23p25, 12, 17q22q25) dim(1p31p36)
NBL-Meta-74 2 4 3 0 19 0 19 — — rev ish enh(17) dim(3, 4, 11, 14, 15)
NBL-Meta-75 2 4 66 0 18 0 18 — U rev ish enh(6q, 17q22q25, 18) dim(3, 5q, 11q22q25, 12q23q24)
NBL-Meta-76 3 4 51 0 4 0 4 — — rev ish enh(4q, 7q, 13q14q34, 17q22q25) dim(1p31p36, 10,
11q21q25, 16q22q24, 17p, 19) amp(2p23p25, 3q25q27)
NBL-Meta-77 3 4 31 1 22 1 22 — U rev ish enh(17q22q25) dim(1p31p36, 9p21p24) amp(2p23p25)
NBL-Meta-78 3 4 42 1 1 1 1 — U rev ish enh(4, 11q14q25, 17q21q25) dim(1p32p36, 17p, 19)
amp(2p22p25)
NBL-Meta-79 3 4 61 1 12 1 12 — U rev ish enh(3q26q29, 4q, 10p, 17q22q25) dim(1p31p36,
3p26q25, 7q32q36, 10q22q34, 17p) amp(2p23p24)
NBL-Meta-80 3 4 20 1 7 1 7 — U rev ish enh(1q, 17q22q25) amp(2p23p24)
NBL-Meta-81 3 4S 3 0 19 0 19 — F rev ish enh(1q23q44, 2p21p25, 17q22q25) dim(1p31p36,
11q22q25, 14q21q32)
NBL-Meta-82 3 4S 1 0 75 0 75 — — rev ish enh(9q33q34, 17q22q25) dim(1p32p36) amp(2p22p24)
NBL-Meta-83 3 4S 1 1 17 1 17 — U rev ish enh(3q24q29) dim(1p34p36) amp(2p23p25)
NBL-Meta-84 1 4S 10 0 74 0 74 — — rev ish enh(7, 13q21q34, 17) dim(3, 4, 14)
NBL-Meta-86 3 4S 4 1 1 1 1 — U rev ish enh(13, 17q22q25) dim(1p35p36, 9, 14, 16p)
amp(2p23p25)
NBL-Meta-87 1 4S 6 0 78 0 78 — U rev ish enh(1q, 5, 6, 7, 8, 9, 12, 13, 14q12q21, 17, 18) dim(1p,
14q22q32, 16)
NBL-Meta-88 3 4S 2 0 67 0 67 — U rev ish enh(2, 7, 13, 17, 18, 20, 21) dim(11, 19)
NBL-Meta-90 1 4S 2 0 49 0 49 — U rev ish enh(6, 7, 13, 15, 17, 18) dim(4, 5, 14, 21)
NBL-Meta-91 1 4S 1 0 46 0 46 — U rev ish enh(2, 6, 7, 12, 13, 17, 18) dim(3)
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NBL-Meta-92 1 4S 3 0 36 0 36 — U rev ish enh(1, 2, 5, 6, 7, 12, 17, 19) dim(3, 4, 8, 9, 10, 11, 14,
18q, 21)
NBL-Meta-93 1 4S 8 0 70 0 70 — U rev ish enh(16p, 17, 19) dim(4q)
NBL-Meta-94 3 4S 4 1 9 1 9 — F rev ish enh(8p, 9q33q34, 12q22q24, 16, 17q22q25, 19, 21)
dim(1p31p36, 4, 5, 6q12q21, 13q21q34, 18) amp(2p23p25)
NBL-Meta-95 1 4S 1 0 20 0 20 — — rev ish enh(2p, 6p21p23, 7, 9q32q34, 12, 17, 19, 20, 22) dim(3q,
4, 5q13q14, 8, 9p22p24, 14)
NBL-Meta-97 1 4S 3 0 2 0 2 — — rev ish enh(1, 2, 6, 7, 10, 12, 13, 17, 18, 20, 22) dim(3, 4, 5, 11,
14)
NBL-Meta-98 1 4S 4 0 7 0 7 — U rev ish enh(7, 12q23q24, 16, 17, 20q, 22) dim(3, 4, 8, 10, 11,
14q21q32, 15q15q26)
NBL-Meta-99 1 4S 8 0 5 0 5 — U rev ish enh(2, 6, 7, 9q22q34, 17, 18p, 22) dim(3, 4, 5, 8q, 11,
14q13q32)
NBL-Meta-100 1 4S 7 0 14 0 14 — — rev ish enh(6p, 7, 12q22q24, 17, 18p, 20, 22) dim(3, 4, 8q, 9, 10,
11, 13q14q22, 14q13q24)
NBL-Meta-101 1 1 11 0 30 0 30 — — rev ish enh(7, 15, 17, 22) dim(9q31q34, 14, X)
NBL-Meta-102 3 1 10 0 41 0 41 — — rev ish enh(2, 12q, 17q) dim(9p, 10)
NBL-Meta-104 1 2 9 0 54 0 54 — — rev ish enh(7, 17, 19) dim(4, 11, X)
NBL-Meta-105 1 2 8 0 83 0 83 tri — rev ish enh(1, 6p, 6q21q27, 7, 11q13, 11p15, 12, 17) dim(4, 21,
X)
NBL-Meta-106 1 2 10 0 15 0 15 — — rev ish enh(2, 17, 19, 21q22, 22q13) dim(3, 4, 9p, 9q12q32, 11,
14, X)
NBL-Meta-107 3 4S 8 0 61 0 61 di — rev ish enh(16, 17, 22q13) dim(1p36, 6q12q21, X) amp(2p23p24)
NBL-Meta-108 1 4S 7 0 40 0 40 tri — rev ish enh(17)
NBL-Meta-109 1 3 24 1 3 1 3 tri — rev ish enh(17, 19, 22) dim(X)
NBL-Meta-110 3 3 60 0 36 0 36 — — rev ish enh(17q21q25) dim(1p, 3p24p26, 4p14p16) amp(2p24)
NBL-Meta-111 1 3 11 0 45 0 45 — — rev ish enh(6, 17) dim(4, 10q25q26)
NBL-Meta-112 1 3 9 0 64 0 64 tri — rev ish enh(7, 8p, 17) dim(10p, X)
NBL-Meta-113 3 4 12 0 42 0 42 tetra — rev ish enh(2p23, 6, 12p, 12q12q24, 17q22q25) dim(1p36, 4p,
9q32q34, 14, 18q22q23, 20)
NBL-Meta-114 3 4 90 1 28 1 28 — — rev ish enh(7, 17q22q25) dim(1p, 10q21q26, 18q22q23, X)
amp(2p24)
NBL-Meta-115 1 4 24 1 11 1 11 — — rev ish enh(2p21p24, 5q32q35, 6p21, 12q24, 17, 19, 22)
dim(1p13p32, 2q22q37, 3p21p26, 5p, 5q11q31, 9p21p24,
11q14q25, 13q21q34)
NBL-Meta-116 2 4 156 1 2 1 2 — — rev ish enh(12q24, 17q22q25) dim(3p24p26, 4p, 11q21q25)
NBL-Meta-117 3 4 30 1 11 1 11 di — rev ish enh(11q13, 17q21q25, 19) dim(1p36) amp(2p24)
NBL-Meta-118 4 4 240 0 21 0 21 di — rev ish dim(5q34q35)
NBL-Meta-119 1 4 10 0 24 0 24 — — rev ish enh(2p, 2q11q31, 7, 17, 21q21q22) dim(3, 4, 8, 9p, 11,
13q14q34)
NBL-Meta-120 3 4 24 1 9 1 9 di — rev ish enh(17q21q25) dim(1p21p36, X) amp(2p24)
NBL-Meta-121 4 4 216 1 18 1 24 — — rev ish enh(1p31q44, 4q12q31, 6p22p25, 12, 17q22q25)
dim(1p32p36, 3, 6q21q27, 14q21q32, X)
NBL-Meta-122 1 4 41 1 10 1 13 — — rev ish enh(1p32p36, 1q, 7, 17q12q25, 19) dim(9p, 14, 18q, 21)
NBL-Meta-124 2 1 8 0 39 0 39 — — rev ish enh(7, 8, 17q) dim(2q22q37, 3, 4, 10, 11, 14)
NBL-Meta-125 4 1 14 0 51 0 51 — — rev ish enh(3, 7, 8, 12, 18) dim(10, 14, X)
NBL-Meta-126 1 1 6 0 36 0 36 — — rev ish enh(6, 7, 8, 12, 13, 15, 17q, 18q) dim(X)
NBL-Meta-127 1 1 2 0 46 0 46 tri — rev ish enh(6, 7, 12, 17)
NBL-Meta-128 1 1 4 0 36 0 36 tri — rev ish enh(1, 2, 7, 12, 17) dim(3, 4, 11, 14, X)
NBL-Meta-129 1 1 1 1 12 0 30 tri — rev ish enh(7, 12, 13, 17, 18, 22) dim(3, 4, 9, 10, 14)
NBL-Meta-130 1 1 5 0 24 0 24 — — rev ish enh(6, 7, 12, 13, 17, 18, 20, 22) dim(3, 14)
NBL-Meta-131 1 1 13 0 18 0 18 tetra — rev ish enh(5, 7, 17) dim(10, X)
NBL-Meta-132 1 1 1 0 13 0 13 tri — rev ish enh(6, 7, 12, 17, 18, 19) dim(4, 8, 14)
NBL-Meta-133 1 1 12 1 4 0 20 tri — rev ish enh(2p23p25, 6, 16, 17, 22) dim(3, 4, 9, 11, 14, X)
NBL-Meta-134 4 1 43.9 0 127.8 0 127.8 di U rev ish enh(7, 12, 20)
NBL-Meta-135 1 1 20.9 0 110.4 0 110.4 tri F rev ish enh(6, 7, 10, 12, 15, 17) dim(3, 4, 14, X)
NBL-Meta-136 1 1 4.5 0 116.8 0 116.8 tetra F rev ish enh(7, 8, 17, 22) dim(3, 4, 11, X)
NBL-Meta-137 1 1 1.4 1 51.5 0 85.8 tri F rev ish enh(2, 5, 7, 8, 13, 17) dim(3, 4, X)
NBL-Meta-139 1 1 48.3 0 74.1 0 74.1 — F rev ish enh(17)
NBL-Meta-140 2 1 93.5 1 15.1 1 73.6 — — rev ish enh(1q, 7, 11p15, 17q12q25, 18) dim(3p, 11q14q25)
NBL-Meta-141 1 2 4.3 0 62.2 0 62.2 tri U rev ish enh(2, 6, 7, 8, 17, 19, 20, 22) dim(3, 4, 9, 11)
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NBL-Meta-142 1 2 13.6 1 17.2 0 64.7 di U rev ish enh(1, 2, 6, 7, 8, 17) dim(3, 4, 11, 14, 15)
NBL-Meta-143 1 2 8.1 0 47 0 47 tri F rev ish enh(6, 7, 15, 17, 22) dim(3, 4)
NBL-Meta-144 1 2 17 1 22 0 41 tri — rev ish enh(6, 7, 8, 17, 22) dim(3, 4, 11, 14, X)
NBL-Meta-145 1 2 13.7 1 1.1 0 57.6 tri F rev ish enh(1p32p36, 7, 12, 17, 19, 22) dim(3, 4, 5, 9, 11, 14, X)
NBL-Meta-146 1 2 19 0 116 0 116 — — rev ish enh(5, 6, 7, 13, 15, 17, 18) dim(19, X)
NBL-Meta-147 1 2 2 0 51 0 51 — — rev ish enh(6, 7, 9, 12, 17, 18) dim(4, 14, 21, X)
NBL-Meta-148 1 2 4 1 4 0 42 — — rev ish enh(6, 7, 17, 20) dim(1p36, 3, 4, 9, 10, 14)
NBL-Meta-149 2 2 23 1 5 0 27 — — rev ish enh(7, 17q) dim(1p36, 2q, 2p11p12, 3, 4, 8, 10, 12)
NBL-Meta-150 2 2 5 1 4 0 27 — — rev ish enh(17q21q25) dim(11q14q25)
NBL-Meta-151 1 2 17 0 28 0 28 — — rev ish enh(7, 13, 17q21q25) dim(11q14q25, 14q22q32)
NBL-Meta-153 1 2 9 0 24 0 24 tri — rev ish enh(7, 13, 17) dim(3, 4, 14)
NBL-Meta-154 1 2 12 0 54 0 54 tri — rev ish enh(6, 7, 17, 22) dim(3, 4, 9, 11, 14)
NBL-Meta-155 3 2 21 0 58 0 58 — — rev ish enh(1p35q44, 2p22q37, 7, 17q) dim(X) amp(2p23p25)
NBL-Meta-156 3 2 4 1 6 1 12 di — rev ish enh(17q22q25) dim(1p32p36) amp(2p23p25)
NBL-Meta-157 1 2 1 0 20 0 20 — — rev ish enh(2, 5, 7, 13, 17, 18) dim(3, 11, X, Y)
NBL-Meta-158 1 2 3 0 32 0 32 — — rev ish enh(1, 2, 5, 12, 13, 17) dim(3, 14, X)
NBL-Meta-159 1 2 24 0 18 0 18 di — rev ish enh(7, 15, 17, 18, 22) dim(11, 14, X)
NBL-Meta-160 1 2 39 0 13 0 13 di — rev ish enh(1, 7, 13, 15, 17, 18, 22) dim(3, 9, 11, 14, 21)
NBL-Meta-161 3 3 47 1 3 1 4 — — rev ish enh(7q32q36, 13) dim(1p33p36, 7p22q31, 8q24,
9p22p24, 11p, 12p13q23, 14, 15, 16, 17p12p13, 18, 20, 21, X)
amp(2p23p25)
NBL-Meta-162 1 3 16 0 72 0 72 — — rev ish enh(7, 8, 13, 17, 18) dim(3, 11, X)
NBL-Meta-163 1 3 16 1 14 1 21 — — rev ish enh(5, 6, 7, 12, 13, 17, 18) dim(4, 8, 14, Y)
NBL-Meta-165 3 3 22 1 17 1 20 — — rev ish enh(6p, 7q, 8, 17q21q25, 18) dim(1p22p36, Y)
amp(2p23p25)
NBL-Meta-167 1 3 3 0 12 0 12 — — rev ish enh(1, 2, 6, 7, 13, 17, 20) dim(11, 14, Xq)
NBL-Meta-168 1 3 21 0 26 0 26 — — rev ish enh(1, 7, 13, 15, 17, 18) dim(3, 9, 11, 14)
NBL-Meta-169 3 3 2 1 2.4 1 2.4 — — rev ish enh(17q21q25) dim(1p34p36) amp(2p24p25)
NBL-Meta-170 1 3 139.9 1 24 1 131.3 tri — rev ish enh(1, 2q, 7, 10, 11q12q22, 12q24, 15, 17q, 18,
Xp11p21) dim(2p, 3, 4, 9, 11q23q25, 14, 21, Xq)
NBL-Meta-171 1 4 16 0 45 0 45 — — rev ish enh(1, 6, 7, 8, 13, 17, 22) dim(3, 11)
NBL-Meta-172 2 4 20 1 7 1 9 — — rev ish enh(1q25q44, 17q21q25) dim(1p31p36) amp(4q33q35)
NBL-Meta-173 2 4 67 1 17 1 20 — — rev ish enh(4q28q35, 5q31q35, 17q21q25, 18) dim(2, 3p14p26,
4p, 10, 11q13q25, 14q21q32) amp(6p12p21)
NBL-Meta-174 3 4 5 1 18 1 41 — — rev ish enh(6p21q27, 17q) dim(1p33p36, 10) amp(2p23p25)
NBL-Meta-175 2 4 39 1 6 1 6 di — rev ish enh(7, 17q21q25, 18) dim(11q14q25)
NBL-Meta-177 2 4 60 1 32 1 40 di — rev ish enh(1q, 7, 8, 17q, 18) dim(3, 9, 10q23q26, 11q21q25, Y)
NBL-Meta-178 1 4 9 0 48 0 48 tri — rev ish enh(2, 6, 7, 12, 13, 17q22q25)
NBL-Meta-179 2 4 29 1 12 1 12 — — rev ish enh(1p34q44, 6p, 7, 17q22q25, 18, 22) dim(1p35p36, 3,
4, 6q14q27, 8, 9, 10, 14, 15, 16, X)
NBL-Meta-180 3 4 61 0 9 0 9 tetra — rev ish enh(1p35q44, 2p22q37, 7, 17q, X) dim(1p36, 3, 5, 10, 15)
amp(2p23p25)
NBL-Meta-181 4 4 20 1 10 1 15 di — rev ish enh(1q, 8q22q23) dim(1p, 8q24, 9p21p24) amp(4q33q35)
NBL-Meta-182 1 4S 6 1 3 0 36 tetra — rev ish enh(1p32q44, 2, 5, 6, 7, 12, 13, 17q21q25, 18)
dim(1p33p36, 3p13p26, 15)
NBL-Meta-183 4 4 31.8 1 14.8 0 92.8 di U rev ish enh(8) amp(5q33q35)
NBL-Meta-184 3 4 9.1 1 11.4 1 15.6 — U rev ish enh(17q12q25) dim(1p) amp(2p24p25)
NBL-Meta-185 3 4 18.4 1 6 1 9 — — rev ish enh(1q, 2, 16, 17q22q25, 18q)
NBL-Meta-186 3 4 38 1 10.2 1 10.2 — — rev ish enh(1p31q44, 3, 5, 17q, 18q22q23) dim(1p32p36,
18p11q21) amp(2p23p25)
NBL-Meta-187 2 4 46.3 0 124.7 0 124.7 — — rev ish enh(17q, 22) dim(4q31q35, 11q14q25)
NBL-Meta-188 3 4 32.6 1 9.7 1 17.7 di — rev ish enh(1q, 17q) dim(1p, 8, 11) amp(2p24p25)
NBL-Meta-189 3 4 56.6 1 27.9 1 34.5 tetra — rev ish enh(1q, 2p22q37, 7, 8, 17q) dim(1p12p34, 3, 9, 11,
13q21q34, 14, 15, 18, X) amp(2p23p25)
NBL-Meta-190 3 4 36.4 1 15.7 1 15.7 — — rev ish enh(1q, 18q) dim(1p36) amp(2p23p25)
NBL-Meta-191 3 4 45 1 14 1 19 di — rev ish enh(6p, 11q, 17q24q25) dim(1p36, 6q22q27)
amp(2p23p25)
NBL-Meta-192 1 4 60 0 36 0 36 di — rev ish enh(7, 11q13, 17q12q25, 19) dim(3p21p26, 4p15p16,
11q14q25, 14q24q32, 21)
NBL-Meta-193 4 4S 4 1 6 1 18 — — rev ish enh(1p31q44, 2p16p25, 6, 7, 12) dim(1p33p36, 10q)
(continued on following page)
Vandesompele et al
2296 JOURNAL OF CLINICAL ONCOLOGY
Copyright © 2005 by the American Society of Clinical Oncology. All rights reserved. 
Downloaded from www.jco.org on March 31, 2005 . For personal use only. No other uses without permission. 
Supplemental Table: Clinical, Genetic, and Histopathologic Parameters and CGH Aberrations for 231 Primary Untreated Neuroblastomas (continued)
Identifier Clustera Stage Ageb Eventc EFSd Survivale OSf Ploidyg INPCh CGH Aberrations
NBL-Meta-194 1 4S 2 1 5 0 47 — — rev ish enh(2p21p25, 3p21q29, 6, 7, 12, 17q21q25, 18q)
dim(1p32p36, 19, 22)
NBL-Meta-195 1 4S 6 0 52 0 52 — — rev ish enh(7, 17) dim(4, 5q11q23, 11, Xp)
NBL-Meta-197 1 4S 4 0 19 0 19 — — rev ish enh(10, 15, 17, 20q, 22) dim(11, 14, X)
NBL-Meta-200 3 4S 2.9 1 7.7 1 15.4 di — rev ish enh(2p21p25) dim(1p35p36)
NBL-Meta-201 1 4S 0.3 0 43.6 0 43.6 di — rev ish enh(2p16p25, 12q15q24, 17) dim(4p15p16)
NBL-Meta-202 1 4S 6.8 0 141.4 0 141.4 — — rev ish enh(1q, 2, 6, 7, 10, 13, 17) dim(3, 4, 8, 14)
NBL-Meta-203 1 4S 6.8 0 118.4 0 118.4 di U rev ish enh(2, 7, 12, 17) dim(3, 4, 5, 9, 10, 14)
NBL-4-01 2 4 61 1 5 1 10 — — rev ish enh(17q21q25) dim(11q21q25)
NBL-4-02 2 4 34 1 3 1 5 — — rev ish enh(1q11q44, 7, 13) dim(1p11p36, 4p11p16, 3, 8, 9, 10,
11, 16)
NBL-4-03 3 4 36 1 6 1 7 — — rev ish dim(1p34p36, 4p15p16)
NBL-4-04 2 4 54 1 7 1 20 — — rev ish enh(2p14p25, 17q11q25, 13) dim(9p12p24, 11q14q25)
NBL-4-05 2 4 29 1 14 1 16 — — rev ish enh(17q22q25) dim(11q14q25)
NBL-4-06 2 4 12 1 8 1 8 — — rev ish enh(17q11q25) dim(11q14q25)
NBL-4-07 4 4 88 1 2 1 4 — — rev ish dim(3p11p26, 11q21q25, 17p11p13)
NBL-4-08 3 4 27 1 10 1 10 — — rev ish enh(17q11q25, 2, 7) dim(8, 9, 11)
NBL-4-09 2 4 38 1 11 1 11 — — rev ish enh(6q23q37, 11p11p15, 17q11q25) dim(3p11p26,
4p14p16, 8p11p23, 11q14q25)
NBL-4-10 2 4 64 0 6 0 6 — — rev ish enh(2p22p25, 13q21q34, 17q22q25) dim(3p21p26,
4p15p16, 11q14q25)
NBL-4-11 2 4 57 0 8 0 8 — — rev ish enh(7q21q36, 17q21q25, 18) dim(11q14q25)
NBL-4-12 2 4 41 1 19 1 20 — — rev ish enh(17q11q25, 13, 18) dim(3p11p26, 11q14q25,
14q24q32, 17p11p13, 10)
NBL-4-13 4 4 38 0 9 0 9 — — rev ish enh(6p22p25, 7p11p14, 7q11q36, 17q11q25, 13)
dim(4q31q35)
NBL-4-14 2 4 9 0 51 0 51 — — rev ish dim(11q14q25)
NBL-4-41 3 4 28 0 14 0 14 — — rev ish enh(2p22p25, 7q21q36, 17q21q25) dim(1p32p36,
4p12p16, 10p11p15, 14q22q34)
NBL-4-42 4 4 19 0 16 0 16 — — rev ish enh(4q11q35, 5q11q23, 13q14q34) dim(4p14p16,
17p11p13, 16, 19, 20, 22)
NBL-4-43 2 4 65 1 10 0 22 — — rev ish enh(12q21q24, 17q11q25) dim(6q24q27, 17p11p13)
NBL-4-44 2 4 44 1 22 0 22 — — rev ish enh(1q11q44, 13q33q34, 17q11q25) dim(9p11p24,
11q14q25, 16q11q24)
NBL-4-45 2 4 36 0 8 0 8 — — rev ish enh(2p15p25, 7q21q26, 17q11q25) dim(11q14q25)
NBL-4-46 2 4 156 0 67 0 67 — — rev ish enh(2p21p25, 10p11p15, 17q11q25, Xp11p22, 17, 18)
dim(3q11q29, 6p11p25, 11q14q25) amp(14q12q13)
NBL-4-47 4 4 84 0 22 0 22 — — rev ish enh(2p16p25, 7q22q26) dim(11q21q25, 14q22q32, 3)
NBL-4-48 2 4 96 0 41 0 41 — — rev ish enh(17q21q25) dim(14q22q32)
NBL-4-49 2 4 84 0 6 0 6 — — rev ish enh(17q21q25, Xp11p22, 18) dim(3p14p26)
NBL-4-50 2 4 47 1 1 1 4 — — rev ish enh(17q21q25, 13) dim(11q14q25)
NBL-4-52 3 4 67 0 10 0 10 — — rev ish enh(7q11q26, 16q22q24, 17q11q25, 12) dim(1p32p36,
4p11p16, 17p11p13, 11) amp(2p24p25)
NBL-01 3 2 6.5 0 156 0 156 — — rev ish enh(2, 7, 17, 18)
NBL-03 1 2 9 0 30 0 30 — F rev ish enh(1, 2, 6, 7, 10, 12, 17, 18) dim(19)
NBL-04 1 2 28.9 0 108 0 108 — — rev ish enh(6, 7, 13, 17, 18) dim(19)
NBL-05 3 2 0.5 0 120 0 120 — U rev ish enh(1, 2, 5, 7, 9, 10, 12, 15, 17, 20, 22)
NBL-06 4 2 54.1 1 8 1 9 — U rev ish enh(2, 3q22qter, 6p, 7q21qter, 12q13q15, 17q)
dim(2q33q35, 10) amp(2p24pter)
NBL-07 3 3 1.4 0 48 0 48 — — rev ish enh(1, 2, 7, 8)
NBL-09 2 4 13.8 NA NA 1 10 — U rev ish enh(17q, 18q) dim(1p32pter) amp(2p24pter, 11q12q14)
NBL-10 3 4 30.7 0 43 0 43 — U rev ish enh(1q, 2, 3p14qter, 4q, 6, 7, 8, 9q, 10q, 11p, 12, 13, 14,
16q, 17q, 18q, 20, 21, 22, Xp) dim(3p21pter, 4p, 11q22qter)
amp(2p24pter, 12q23)
NBL-11 3 4 59.4 1 11 1 23 — U rev ish enh(1q, 2p24pter, 4q31q31, 5p15, 5q31, 7q, 12, 16, 17q,
18q, 20q, 22, Xp22)
NBL-12 3 4S 1.8 0 31 0 31 — — rev ish enh(1, 2, 9, 13, 15, 17)
NBL-13 4 4 32.4 1 27 1 40 — — rev ish enh(6p, 9q11, 15, Xp22)
NBL-14 3 4 24.6 1 13 1 14 — U rev ish enh(2p13pter, 17q) dim(1p32pter) amp(2p24pter)
NBL-15 2 4 23.8 1 19 1 22 — U rev ish enh(17q) dim(17p) amp(2p24pter)
NBL-16 3 4 11.3 1 13 1 16 — U rev ish enh(1p31qter, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17q, 18q, 19, 20, 21, 22) amp(2p24pter)
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